View prostate cancer trials »

3-Dimensional Transrectal Ultrasound for Prostate Cancer Diagnosis and Surveillance
Aims: To evaluate the impact of using a 3-dimensional transrectal ultrasound for diagnosis and surveillance of prostate cancer. Before the Food and Drug Administration (FDA) approved 3-D ultrasounds, all prostate biopsies were performed using 2-dimensional images. The 3-D technology potentially allows for better visualization to increase accuracy of needle placement when sampling different parts of the prostate. The study involves access to your medical record and does not include any additional procedures.
Diagnosis: Undergoing 3-D Prostate Biopsy
Principal Investigator: Michael McGuire, MD
IRB Approval Number: EH10-379
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator Jackie Petkewicz at 847.503.4282
Open to Enrollment: Yes

Prostate Cancer Susceptibility: The ICPCG Study (International Consortium for Prostate Cancer Genetics)
Aims: To determine the genetic basis of prostate cancer. Families with at least two men affected with prostate cancer are likely to harbor genetic susceptibility to the disease. By studying these families, researchers may identify new genes or genetic mutations that may predispose certain men to prostate cancer or aggressive disease. The study involves a one-time blood draw and a minimal one-time questionnaire.
Diagnosis: A Family History of Prostate Cancer
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH13-250
Sponsor:  John and Carol Walter Center for Urological Health
Contact: Study Coordinator Jasmine Nero at 847.503.3087
Open to Enrollment:
Yes

Phenotyping Study Protocol
Aims: To provide valuable information to researchers about patients' experiences with urinary symptoms and how the symptoms are managed by the urologist. We want to understand the important differences among people and what factors affect urinary and bladder problems. The ultimate goal of this study is to collect information that will improve the care and treatment for people with urinary and bladder problems.
Diagnosis: Lower Urinary Tract Symptoms Patients Seeing a Urologist for the First Time 
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH15-143
Sponsor: National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Contact: Study Coordinator Pooja Talaty at 847.503.4280
Open to Enrollment: Yes

Compliance and Outcomes with Penile Rehabilitation in Men after Prostate Cancer Treatment
Aims: To determine the impact of sexual function rehabilitation on quality of life in men who have undergone prostate cancer treatment with either surgery or radiation therapy. Treatment compliance and satisfaction will be measured. The study involves periodic questionnaires.
Diagnosis: Sexual Dysfunction following Prostate Cancer Treatment 
Principal Investigator: Jeffrey Albaugh, PhD, APRN
IRB Approval Number: EH13-049
Sponsor: NorthShore University HealthSystem
Contact: Nurse Navigator, Martha McCurdy at 847.503.4245 or Study Coordinator, Nat Sufrin at 847.503.4281
Open to Enrollment: Yes

Clinical Validation of a Urine-Based Assay with Genomic and Epigenomic Markers for Predicting Recurrence during Non-Miscle Invasive Bladder Cancer Surveillance
Aims: To determine the ability of a experimental urine test to detect recurrence in patients with previously-diagnosed bladder cancer.  The sponsor hopes that this new test will reduce the need for cystoscopy in patients who are unlikely to have a recurrence and improve compliance in patients who need to have a cystoscopy.
Diagnosis: Low Grade, Non-Invasive Bladder Cancer
Principal Investigator: Brian Helfand, MD, PhD
IRB Approval Number: EH16-009
Sponsor: NorthShore University HealthSystem
Contact: Study Coordinator Jasmine Nero at 847.503.3087 
Open to Enrollment: Yes

× Alternate Text